Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk

The relative efficacy and safety of more potent P2Y inhibitors in patients with acute coronary syndrome and high bleeding risk (HBR) undergoing percutaneous coronary intervention remains unclear. We aimed to study the treatment effect of ticagrelor and prasugrel in percutaneous coronary intervention...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Circulation. Cardiovascular interventions 2022-10, Vol.15 (10), p.e012204-e012204
Hauptverfasser:	Lahu, Shqipdona, Presch, Antonia, Ndrepepa, Gjin, Menichelli, Maurizio, Valina, Christian, Hemetsberger, Rayyan, Witzenbichler, Bernhard, Bernlochner, Isabell, Joner, Michael, Xhepa, Erion, Hapfelmeier, Alexander, Kufner, Sebastian, Rifatov, Nonglag, Sager, Hendrik B., Mayer, Katharina, Kessler, Thorsten, Laugwitz, Karl-Ludwig, Richardt, Gert, Schunkert, Heribert, Neumann, Franz-Josef, Sibbing, Dirk, Angiolillo, Dominick J., Kastrati, Adnan, Cassese, Salvatore
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - drug therapy Hemorrhage - chemically induced Humans Percutaneous Coronary Intervention - adverse effects Platelet Aggregation Inhibitors - adverse effects Prasugrel Hydrochloride - adverse effects Risk Assessment Ticagrelor - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!